Macclesfield-based Bitrobius Genetics secures £700k from ARIA and SCVC
This article covers Bitrobius Genetics, a biotech startup, which has raised £700k in a pre-seed funding round to extend its Gentrafix platform to the delivery of DNA into mitochondria. The funding supports a collaboration with the Mitochondrial Biology Unit at the University of Cambridge to pursue preclinical delivery work that aims to enable therapeutic approaches for inherited mitochondrial disorders and other conditions linked to mitochondrial dysfunction.
Bitrobius Genetics, a biotech startup based in Macclesfield, has raised £700,000 in a pre-seed funding round to extend its Gentrafix platform to the long-standing problem of delivering DNA into mitochondria. The funds will support a collaboration with the Mitochondrial Biology Unit at the University of Cambridge to explore whether Bitrobius’ approach can cross the double mitochondrial membrane and enable wider delivery of therapeutic DNA inside cells.
Why it matters
Mitochondrial DNA mutations cause a group of severe inherited diseases for which there are few treatment options. Unlike nuclear genes, mitochondrial genomes sit inside a double membrane that has proved a major barrier to conventional gene-delivery techniques. If researchers can reliably get DNA into mitochondria, it could open therapeutic avenues not only for inherited mitochondrial disorders but also for conditions where mitochondrial dysfunction plays a role, such as some neurodegenerative diseases, cancer, diabetes and ageing.
The announcement is notable because it targets one of molecular medicine’s tougher technical problems. Progress here would shift part of the therapeutic landscape beyond the nucleus and could increase the range of diseases addressable by genetic medicines.
Inside the product
Bitrobius’ core technology, Gentrafix, is described as a plasmid-based platform designed to replicate within human cells and propagate to neighbouring cells, potentially increasing the proportion of treated cells compared with many current gene therapies. The company says it will adapt Gentrafix to deliver DNA across the mitochondrial double membrane using a proprietary DNA-secreting pore.
The challenge is twofold: engineered DNA needs to enter the mitochondrial compartment, and any therapeutic construct must function alongside or replace defective mitochondrial genomes. The project with Cambridge’s Mitochondrial Biology Unit focuses on the delivery mechanism rather than clinical proof of efficacy, positioning this as preclinical research into a delivery solution that, if successful, could be used across multiple indications.
Who are the investors?
The £700,000 announced is grant funding. Backing to date for Bitrobius includes seed investments from Science Creates Ventures (SCVC), Future Planet Capital, Synbioven and Catapult Ventures, together with prior grant funding from Innovate UK. The new award will fund the collaboration with the Mitochondrial Biology Unit at the University of Cambridge.
The funder of the latest grant is the UK’s Advanced Research + Invention Agency (ARIA), which supports high-risk, high-reward research. The combination of venture backing and public grants reflects a common early-stage funding mix in UK biotech: private seed capital to develop a platform and public funding to de-risk technically ambitious experimental work.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
Rocky Cranenburgh, Founder & CEO at Bitrobius Genetics, said:
We are excited to receive the funding to apply our groundbreaking technology to the ambitious challenge of DNA delivery to mitochondria, thanks to the support of ARIA and the Mitochondrial Biology Unit at the University of Cambridge.
Michal Minczuk, Professor of Mitochondrial Genetics at the University of Cambridge, said:
We are excited to combine Bitrobius' innovative technology with our expertise in mitochondrial genetics to tackle one of the field's most longstanding challenges: delivering DNA into mitochondria.
The bigger picture
The project sits at the intersection of synthetic biology and genetic medicines research, where many UK groups are attempting to solve delivery and specificity problems that limit therapeutic impact. ARIA’s involvement signals continued public interest in funding high-risk lab research that traditional grant mechanisms may struggle to support.
If the Gentrafix approach can be adapted for mitochondrial delivery, it would add a new modality to the UK biotech toolkit and could attract further private investment into platform-focused genetics companies. The collaboration between an industry-led team in Macclesfield and an academic unit in Cambridge also underlines the role of university partnerships in translating foundational biology into potential therapies.
This development will be one to watch for UK and European biotech observers: successful technical progress could influence both funding priorities and the focus of early-stage investors across the region.
They've invested in Bitrobius Genetics
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Science Creates Ventures (SCVC)( ) | ||||
 Future Planet Capital( ) Future Planet Capital is an impact-led venture capital firm founded in the UK wi... London  | ||||
 | ||||
 Catapult Ventures( ) | ||||
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK